Publication | Open Access

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

InflammationRheumatologyPlacebo-controlled Phase 2Autoimmune DiseaseImmunologyGastroenterologyModerate-to-severe CrohnUlcerative ColitisMedicineInflammatory DiseaseInduction Therapy